We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.3B
AUM Growth
-$82M
Cap. Flow
-$615M
Cap. Flow %
-7.41%
Top 10 Hldgs %
34.19%
Holding
170
New
23
Increased
24
Reduced
50
Closed
20

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$104M
2
CI icon
Cigna
CI
+$77.7M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$73.5M
4
MOH icon
Molina Healthcare
MOH
+$62.4M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$125M
2
BIIB icon
Biogen
BIIB
+$88.7M
3
SEM
Select Medical
SEM
+$77.6M
4
MRK icon
Merck
MRK
+$75.8M
5
FOLD
Amicus Therapeutics
FOLD
+$74.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.81%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
101
DELISTED
Radius Health, Inc.
RDUS
$13.6M 0.16%
762,900
– –
TECX
102
Tectonic Therapeutic
TECX
$562M
$13M 0.16%
20,833
– –
NBRV
103
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$12.5M 0.15%
18,578
+2,900
+18% +$2.06M
WMGIZ
104
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$12.2M 0.15%
8,746,583
– –
ELDN icon
105
Eledon Pharmaceuticals
ELDN
$262M
$11.8M 0.14%
140,951
– –
GBT
106
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11.8M 0.14%
309,500
-137,775
-31% -$6.1M
ACIU icon
107
AC Immune
ACIU
$236M
$11.5M 0.14%
+1,440,000
New +$14.5M
DERM
108
DELISTED
Dermira, Inc.
DERM
$11.2M 0.14%
1,031,596
– –
CTIC
109
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$10.8M 0.13%
5,000,000
– –
HCA icon
110
HCA Healthcare
HCA
$92.8B
$10.6M 0.13%
75,900
-161,400
-68% -$20.1M
MCK icon
111
McKesson
MCK
$104B
$9.83M 0.12%
+74,100
New +$9.66M
ADAP
112
DELISTED
Adaptimmune Therapeutics
ADAP
$9.04M 0.11%
666,593
– –
ALLK
113
DELISTED
Allakos
ALLK
$9M 0.11%
+200,000
New +$8.21M
XENE icon
114
Xenon Pharmaceuticals
XENE
$6.28B
$8.38M 0.1%
634,812
– –
LAB icon
115
Standard BioTools
LAB
$311M
$8.07M 0.1%
1,077,801
-505,899
-32% -$3.6M
NVTR
116
DELISTED
Nuvectra Corporation Common Stock
NVTR
$7.69M 0.09%
+350,000
New +$6.73M
BMRN icon
117
BioMarin Pharmaceuticals
BMRN
$12B
$7.42M 0.09%
76,500
– –
YI
118
111 Inc
YI
$34.7M
$6.76M 0.08%
+50,000
New +$6.99M
ATNX
119
DELISTED
Athenex, Inc. Common Stock
ATNX
$6.68M 0.08%
21,500
– –
MCK icon
120
CALL
McKesson
MCK
$104B
$6.63M 0.08%
+50,000
New +$6.52M
ALKS icon
121
Alkermes
ALKS
$8.47B
$6.15M 0.07%
145,000
– –
MRNS
122
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.68M 0.07%
141,900
– –
CNST
123
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$5.63M 0.07%
+835,842
New +$7.96M
ECOR icon
124
electroCore
ECOR
$50.5M
$5.57M 0.07%
26,548
– –
VTAK icon
125
Catheter Precision
VTAK
$1.01M
$5.46M 0.07%
+1
New +$4.54M
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2018 Portfolio in Review

As of Q3 2018, OrbiMed held 170 positions worth $8.3B, down 0.98% from $8.38B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $615M in Q3 2018, closing 20 positions and reducing 50 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $125M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Principia Biopharma Inc. Common Stock worth $76.1M.

  • OrbiMed's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,605,713 shares worth $76.1M.
  • OrbiMed added most to Humana in Q3 2018, an estimated $104M increase.
  • OrbiMed's biggest Q3 2018 reduction was Biogen, cutting an estimated $88.7M.
  • OrbiMed fully exited Alnylam Pharmaceuticals in Q3 2018, selling an estimated $125M.
  • OrbiMed's ten largest holdings make up 34% of its $8.3B portfolio in Q3 2018.
  • OrbiMed opened 23 new positions and closed 20 in Q3 2018.
  • OrbiMed's portfolio value fell 0.98% quarter-over-quarter to $8.3B.

Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.